February 14, 2024 Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease ...
February 1, 2024 Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline ...
January 25, 2024 Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions ...
January 4, 2024 Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare ...
January 3, 2024 BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare ...
January 3, 2024 Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 ...
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline
Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions
Celularity Releases CEO Letter to Shareholders
Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare
BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare
Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023